Cholera Clinical Trial
Official title:
Assessment of a Novel Fixed-dose Combination (FDC) Drug VR-AD-1005 for the Treatment of Acute Watery Diarrhea in Cholera: a Phase II, Randomized, Placebo-controlled, Double-blinded Efficacy and Safety Trial
Cholera still remains a global public health concern affecting both children and adults, and patients can succumb in quick time if remain untreated. Cholera is a secretory diarrhea and is generally treated with oral or intravenous rehydration therapy to compensate for the fluid loss. However, antimicrobial treatment is given to patients with moderate to severe diarrhea. The consistent emergence of multidrug-resistant bacteria is a major concern for the management of infectious diseases including cholera. No antisecretory drug has so far been proven successful. In a phase II clinical trial, the investigators will assess the effectiveness of a novel antisecretory drug VR-AD-1005 for treating cholera. Changes in stool volume and rehydration therapy will be assessed for VR-AD-1005 in comparison with placebo. If successful, this will be a huge advance in managing cholera and other secretory diarrhea. The introduction of the antisecretory drug can minimize the hospital stay and reduce antibiotic use, which in turn can reduce the emergence of antibiotic resistance among pathogens
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01895855 -
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
|
Phase 3 | |
| Completed |
NCT01339845 -
Introduction of Cholera Vaccine in Bangladesh
|
N/A | |
| Recruiting |
NCT05829772 -
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
|
||
| Completed |
NCT04760236 -
Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™
|
Phase 3 | |
| Recruiting |
NCT04326478 -
Single Dose Azithromycin to Prevent Cholera in Children
|
Phase 2 | |
| Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
| Completed |
NCT02928341 -
Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo
|
N/A | |
| Completed |
NCT02864433 -
Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
|
||
| Recruiting |
NCT06003816 -
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
|
N/A | |
| Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
| Completed |
NCT04150250 -
Cholera Anti-Secretory Treatment Trial
|
Phase 2 | |
| Terminated |
NCT00624975 -
Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants
|
Phase 2 | |
| Completed |
NCT00226616 -
Zinc Supplementation in Cholera Patients
|
Phase 3 | |
| Completed |
NCT03373669 -
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
|
Phase 4 | |
| Completed |
NCT02100631 -
A Study of Live Oral Cholera Vaccine, PXVX200 in Healthy Older Adults
|
Phase 3 | |
| Completed |
NCT02094586 -
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
|
Phase 3 | |
| Completed |
NCT01823939 -
PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera
|
Phase 1 | |
| Completed |
NCT01365442 -
Pilot Introduction of Oral Cholera Vaccine in Orissa, India
|
N/A | |
| Completed |
NCT00128011 -
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine
|
Phase 2 | |
| Completed |
NCT00672308 -
Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults
|
Phase 2 |